We showed that in prostate cancer patients before therapy both the adaptive immune system (altered CD4+ Teff cells and increased fraction of Tregs with suppressive phenotype) and the innate immune system (decreased NK cell fraction) were altered. The gene discussed is CD4; the disease is prostate carcinoma.